Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Vishant Ramadorai

Gastroenterology Fairfax, VA Medical Doctor

NPI 1467848473 CMS profile 9571151

3028 Javier Rd Ste 300, Fairfax, VA 22031

Open in the dashboard

General payments

$9,137

460 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vishant Ramadorai of Fairfax, VA is reported in the CMS Open Payments database as having received $9,137 across 460 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,889 138
2024 General $2,371 116
2023 General $2,272 119
2022 General $1,409 76
2021 General $196 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vishant Ramadorai
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Vishant Ramadorai were reported at $2,889. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Vishant Ramadorai Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $196 $352 $106–$1,054 $132
2022 $1,409 $448 $129–$1,270 $149
2023 $2,272 $533 $150–$1,390 $160
2024 $2,371 $605 $160–$1,606 $164
2025 $2,889 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,925 122 payments
  2. Janssen Biotech, Inc. $944 42 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $762 35 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $706 36 payments
  5. Celgene Corporation $655 42 payments
  6. Gilead Sciences, Inc. $584 28 payments
  7. Pfizer Inc. $541 25 payments
  8. Ipsen Biopharmaceuticals, Inc $368 11 payments
  9. Genzyme Corporation $302 16 payments
  10. Celltrion USA Inc. $223 10 payments
  11. Other $2,128 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,993 453 payments
  2. Education $143 7 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $863 39 payments
  2. RINVOQ $843 50 payments
  3. ZEPOSIA $655 42 payments
  4. CREON $643 35 payments
  5. TREMFYA $571 25 payments
  6. LINZESS $565 35 payments
  7. ENTYVIO $540 27 payments
  8. XELJANZ $398 18 payments
  9. SKYRIZI $379 33 payments
  10. STELARA $372 17 payments
  11. Other $4,510 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

535

Median for Gastroenterology: 569

Drug cost

$238,340

Median for Gastroenterology: $104,976

Branded share of claims

38.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 32 $102,320
Creon Lipase/Protease/Amylase Brand 37 $97,589
Linzess Linaclotide Brand 18 $12,849
Ursodiol Generic 22 $8,800
Mesalamine Generic 13 $4,546
Azathioprine Generic 20 $2,609
Entecavir Generic 15 $2,277
Pantoprazole Sodium Generic 127 $1,258
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 21 $1,173
Tenofovir Disoproxil Fumarate Generic 11 $985

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$194,561

Of which drugs: $69,646

Medicare patients

538

Average age 73

Services billed

5,256

293 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 48%
Diabetes 29%
Ischemic heart disease 29%
Chronic kidney disease 21%
Cancer 18%
Atrial fibrillation 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $202
$202 — —
LINZESS
  • AbbVie, Inc. $159
  • Ironwood Pharmaceuticals, Inc $41
$200 18 —
TREMFYA
  • Janssen Biotech, Inc. $195
$195 — —
CREON
  • AbbVie, Inc. $156
$156 37 —
ZEPOSIA
  • Celgene Corporation $155
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record